炎症性肠病诊断前分子谱分析的兴起——能否在马跑掉之前关上门?
炎症性肠病(IBD)通常在症状出现后依据典型肠道炎症模式诊断,但越来越多证据提示其存在漫长的生物学活跃临床前期。对大型纵向健康人群队列存档生物样本的分析发现,临床发病前多年即可检测到抗菌与自身反应性抗体滴度升高及循环免疫活性蛋白网络紊乱。整合这些分子特征或可识别 destined 发展为IBD的个体并推测临床前驱动因素,为开发可扩展生物标志物组合以拦截IBD提供时机。
要点
- IBD存在临床前生物学活跃期,发病前多年可检测分子异常。
- 抗菌与自身抗体滴度升高及循环免疫蛋白网络紊乱是早期特征。
- 整合多分子特征有望构建生物标志物组合用于临床前检测。
核心结论
- 炎症性肠病存在漫长的生物学活跃临床前期,临床发病前多年即可检测到多种分子特征。
- 整合多种分子特征有望开发可扩展生物标志物组合,用于检测临床前疾病并主动拦截IBD发生。
研究设计与样本
- 基于大型纵向健康人群队列研究存档生物样本的分析,部分个体随后发生IBD。
主要发现
- 临床发病前多年可检测到抗菌和自身反应性抗体滴度升高。
- 循环免疫活性蛋白网络存在紊乱,涉及单核吞噬细胞-淋巴细胞相互作用失调和趋化性增强。
- 常见干扰素-γ驱动的趋化因子程序,并有早期组织损伤证据如循环细胞外基质成分和金属蛋白酶增加。
- 循环抗细菌和抗病毒抗体反应升高提示宿主-微生物相互作用紊乱可能是健康向早期疾病转变的潜在触发因素。
临床怎么用
- 目前尚无临床可用的临床前IBD生物标志物组合,需进一步开发可扩展且临床可行的检测面板。
局限性
- 血清学反应可能是与早期黏膜损伤和微生物易位相关的伴随现象,而非因果驱动因素。
- 临床前IBD的潜在近端驱动因素仍属推测,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inflammatory bowel disease (IBD) is typically diagnosed after the onset of symptoms in the context of established, characteristic patterns of intestinal inflammation. However, there is now substantial evidence pointing to a prolonged, biologically active preclinical phase of disease. Analysis of archived biological samples from large-scale longitudinal cohort studies of healthy individuals, some of whom develop incident IBD, has identified different molecular features that can be detected many years before clinical presentation. These include increased titres of antimicrobial and autoreactive antibodies and perturbations in a complex network of circulating, immunologically active proteins. As well as affording 'diagnostic' opportunities to identify individuals destined to develop IBD, an integrated view of these multiple different molecular features enables speculation of potential proximal drivers of preclinical IBD. Consistently recognised associations include dysregulated mononuclear phagocyte-lymphocyte interactions, augmented chemotaxis, frequently relating to interferon-γ-driven chemokine programmes and evidence of early tissue injury, such as increased circulating extracellular matrix components and metalloproteinases. Increased levels of circulating antibacterial and antiviral antibody responses hint towards disordered host-microbe interactions as potential prime triggers for the transition between health and early disease, although it is possible that these serological responses are an epiphenomenon linked to early mucosal damage and microbial translocation. There is now a timely opportunity to develop these different molecular features into scalable and clinically tractable biomarker panels to detect preclinical disease and enable strategies to proactively intercept IBD before it even develops.
引用
- Powell N. Rise of prediagnostic molecular profiling in inflammatory bowel disease-can we close the door before the horse has bolted? Gut. 2026. PMID: 41690702. doi:10.1136/gutjnl-2025-336049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。